Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland.
Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, 1001 Tirana, Albania.
Cells. 2023 Feb 13;12(4):609. doi: 10.3390/cells12040609.
Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone produced mainly in osteocytes. In chronic kidney disease (CKD) FGF23 levels increase due to higher production, but also as the result of impaired cleavage and reduced excretion from the body. FGF23 has a significant role in disturbed bone and mineral metabolism in CKD, which leads to a higher cardiovascular risk and mortality in these patients. Current research has emphasized the expression of FGF23 in cardiac myocytes, fibroblasts, and endothelial cells, and in addition to the effects on the kidney, its primary role is in cardiac remodeling in CKD patients. Recent discoveries found a significant link between increased FGF23 levels and anemia development in CKD. This review describes the FGF23 role in cardiac hypertrophy and anemia in the setting of CKD and discusses the best therapeutical approach for lowering FGF23 levels.
成纤维细胞生长因子 23（FGF23）是一种主要在骨细胞中产生的磷酸尿激素。在慢性肾脏病（CKD）中，由于产生增加，以及裂解受损和从体内排泄减少，FGF23 水平升高。FGF23 在 CKD 中骨骼和矿物质代谢紊乱中具有重要作用，这导致这些患者的心血管风险和死亡率更高。目前的研究强调了 FGF23 在心肌细胞、成纤维细胞和内皮细胞中的表达，除了对肾脏的影响外，其主要作用是在 CKD 患者的心脏重构中。最近的发现发现，在 CKD 中，FGF23 水平升高与贫血的发展之间存在显著关联。这篇综述描述了 FGF23 在 CKD 中心脏肥大和贫血中的作用，并讨论了降低 FGF23 水平的最佳治疗方法。
